Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the Ontology.
Abiraterone & Enzalutamide
Regimen
Hormonotherapy
CE & Ipilimumab
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
EP & Ipilimumab
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
FULV & Trimetrexate
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Ixabepilone & Bevacizumab
Regimen
Chemotherapy
Targeted therapy
MFL
MFL: Methyl-lomustine (MeCCNU), 5-FU & LeucoVorin (Folinic acid)
Regimen
Chemotherapy
Mitoxantrone & Hydrocortisone
Regimen
Chemotherapy
Hormonotherapy
TG+Bev
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab
Regimen
Chemotherapy
Targeted therapy